MetaCap

Arvinas (ARVN) vs Oculis (OCS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arvinas (ARVN) has outperformed Oculis (OCS) over the past year, losing 43.9% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -91.8% for ARVN. Arvinas is the larger company by market cap ($423.0 million vs $393.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARVN-43.92%OCS-63.34%
+76%+2%-71%
Nov 21, 20251 yearNov 20, 2026
ARVN-92.22%OCS-27.66%
+251%+71%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARVN versus OCS key metrics
MetricARVNOCS
Share price$6.46$7.06
Market cap$423.03M$393.35M
1-day change-4.15%-5.11%
YTD return-45.53%-64.65%
1-year return-43.92%-63.34%
5-year return-91.75%-27.29%
EPS (TTM)$-0.08$-1.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$262.60M—
Revenue growth (YoY)-0.30%—
Net income (latest FY)$-80.80M—
Operating margin-45.13%—
Net margin-30.77%—
52-week high$14.51$34.48
52-week low$6.33$6.78
Distance from 52-week high-55.48%-79.52%
Analyst consensusbuystrong_buy
Avg. price target upside+116.72%+407.79%
Average volume848.52K272.83K
Shares outstanding65.49M55.72M
Employees24660
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARVN has outperformed OCS by 19.4 percentage points over the past year.

About Arvinas

ARVN stock →

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees

About Oculis

OCS stock →

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

ARVN vs OCS FAQ

Which is bigger, Arvinas or Oculis?

Arvinas (ARVN) is larger, with a market capitalization of $423.03M compared with $393.35M for Oculis (OCS).

Which stock has performed better over the past year, ARVN or OCS?

ARVN returned -43.92% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.

Are Arvinas and Oculis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons